Immuneering Corporation
NASDAQ:IMRXBiotechnology
-$0.01 today
- Market cap
- $226.67M
- Beta
- 0.38
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.24
Volume 0.73M
Average 1.38M
IMRX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Immuneering CorporationNASDAQ: IMRX
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $18.51M (cash outflow) rose 31.4% year over year, ahead of the -7.0% change in trailing-twelve-month free cash flow. Sequentially, it rose 85.8% from the prior quarter. Over 3 fiscal years it compounded at +0.5% a year.
Context
- Free cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +31.4% holds above the trailing-twelve-month pace of -7.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (45.49M) USD
- Year-over-year change
- +17.4%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (45.49M) | +17.4% |
| FY2024 | 2024-12-31 | (55.08M) | -11.7% |
| FY2023 | 2023-12-31 | (49.31M) | -10.0% |
| FY2022 | 2022-12-31 | (44.84M) | -45.1% |
| FY2021 | 2021-12-31 | (30.91M) | — |
Free Cash Flow vs competitors
How IMRX compares with its peers on the latest reported figures
- IMRX's LTM Mar 2026 free cash flow of $49.91M is the 9th largest of the 11 companies compared; the peer median is $65.8M.
- Its year-over-year change of -7.0% is the 5th highest of 11, against a peer median of -10.5%.
- Over three fiscal years its annual growth of +0.5% compares with a peer median of -5.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $131.64M | +126.9% | +10.3% | 2294.2% | |
| LTM Mar 2026 | $102.38M | +1.6% | +13.6% | 5078.2% | |
| LTM Mar 2026 | $87.42M | -8.8% | — | 309.7% | |
ZURAZura Bio Limited | LTM Mar 2026 | $72.75M | +112.3% | +70.1% | — |
| LTM Mar 2026 | $66.98M | +12.6% | -12.8% | 483.3% | |
| LTM Mar 2026 | $64.63M | -24.7% | -18.0% | 28725.3% | |
| LTM Mar 2026 | $58.89M | -34.5% | — | 129.9% | |
| LTM Mar 2026 | $51.43M | -12.1% | +2.6% | — | |
| LTM Mar 2026 | $49.91M | -7.0% | +0.5% | — | |
| LTM Mar 2026 | $39.84M | -29.1% | -21.3% | 56.0% | |
| LTM Mar 2026 | $9.61M | -88.3% | -28.2% | 13.9% | |
| Peer median (excluding IMRX) | $65.8M | -10.5% | -5.1% | 396.5% | |
Competitors are the stored peer set for IMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (33.54M) | (50.51M) | (53.47M) | (61.04M) | (56.02M) |
| Depreciation & Amortization | 159.07K | 796.79K | 352.08K | 385.07K | 698.89K |
| Deferred Income Tax | (307.49K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.8M | 0 | 5.73M | 6.5M | 0 |
| Change in Working Capital | 900.42K | 1.72M | (974.64K) | (925.38K) | 3.82M |
| Accounts Receivables | 279.71K | 233.62K | 12.42K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (130.4K) | 1.76M | (1.11M) | (112.14K) | (400.8K) |
| Other Working Capital | 751.1K | (276.56K) | 119.84K | (813.24K) | 4.22M |
| Other Non-Cash Items | 130.24K | 3.9M | (601.59K) | 75.98K | 6.16M |
| Operating Cash Flow | (30.85M) | (44.1M) | (48.97M) | (55M) | (45.34M) |
| Capital Expenditures | (60.79K) | (742.49K) | (342.75K) | (84.88K) | (142.23K) |
| Acquisitions (Net) | 70.35K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (75.63M) | (50.1M) | (44.66M) | (5.41M) | (88.6M) |
| Sales of Investments | 75.62M | 92.68M | 52.3M | 31.93M | 0 |
| Other Investing Activities | (75.62M) | 0 | 0 | 0 | 247 |
| Investing Cash Flow | (75.62M) | 41.83M | 7.3M | 26.43M | (88.74M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 120.32M | 19K | 28.2M | 4.24M | 226.58M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (842.76K) | 0 | 241.07K | 1.07M | (147) |
| Financing Cash Flow | 144.26M | 19K | 28.44M | 5.3M | 226.58M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.8M | (2.25M) | (13.23M) | (23.26M) | 92.5M |
| Free Cash Flow | (30.91M) | (44.84M) | (49.31M) | (55.08M) | (45.49M) |
Immuneering Corporation
NASDAQ:IMRX
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.